Literature DB >> 2425947

Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples.

W Jonat, H Maass, H E Stegner.   

Abstract

A new estrogen receptor immunocytochemical assay (ER-ICA) which uses monoclonal antibodies to the estrogen receptor protein was applied to 97 breast cancer tissues. The results were correlated to those obtained by conventional dextran coated charcoal assays. The presence or absence of nuclear staining was significantly associated with positive or negative estrogen receptor status by dextran-coated charcoal (P less than 0.001). Furthermore ER-ICA results showed a high degree of correlation with a light microscopic grading. The relationship between ER-ICA results and response to endocrine therapies in patients with advanced disease was assessed in 20 patients. Six of 11 (55%) ER-ICA positive patients responded, whereas 8 of 9 (89%) ER-ICA negative patients failed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425947

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  The forensic value of the immunohistochemical detection of oestrogen receptors in vaginal epithelium.

Authors:  R Hausmann; M Baltzer; B Schellmann
Journal:  Int J Legal Med       Date:  1996       Impact factor: 2.686

2.  Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells.

Authors:  Yan Liu; Shi-Yong Sun; Taofeek K Owonikoko; Gabriel L Sica; Walter J Curran; Fadlo R Khuri; Xingming Deng
Journal:  Mol Cancer Ther       Date:  2011-11-04       Impact factor: 6.261

3.  Estrogen receptor determinations in primary breast cancer. A comparison of a biochemical dextran-coated charcoal and an immunohistological technique.

Authors:  S von Kleist; J Berling; J Koltzenburg; H Gropp
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

4.  Quantification of oestrogen receptors in breast cancer: radiochemical assay on cytosols and cryostat sections compared with semiquantitative immunocytochemical analysis.

Authors:  H M Scheres; A F De Goeij; M J Rousch; G G Hondius; D D Willebrand; A H Gijzen; F T Bosman
Journal:  J Clin Pathol       Date:  1988-06       Impact factor: 3.411

5.  Influence of endocrine status on biochemical and immunocytochemical estrogen and progesterone receptor assays in breast cancer patients.

Authors:  H J Helin; J J Isola; M J Helle; H Adlercreutz
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

6.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.

Authors:  Malini Harigopal; William E Barlow; Greg Tedeschi; Peggy L Porter; I-Tien Yeh; Charles Haskell; Robert Livingston; Gabriel N Hortobagyi; George Sledge; Charles Shapiro; James N Ingle; David L Rimm; Daniel F Hayes
Journal:  Am J Pathol       Date:  2010-02-11       Impact factor: 4.307

7.  Effects of tamoxifen on human breast cancer cells in vitro.

Authors:  W E Simon; G Trams; F Hölzel
Journal:  Arch Gynecol Obstet       Date:  1993       Impact factor: 2.344

8.  Estrogen receptor determination by monoclonal antibody in fine needle aspiration breast cancer cytologies: a marker of hormone response.

Authors:  G V Burton; J L Flowers; E B Cox; G S Leight; G A Dent; K R Geisinger; K S McCarty; K S McCarty
Journal:  Breast Cancer Res Treat       Date:  1987-12       Impact factor: 4.872

9.  Estrogen and progesterone receptors in thyroid lesions.

Authors:  B R Jaklic; J Rushin; B C Ghosh
Journal:  Ann Surg Oncol       Date:  1995-09       Impact factor: 5.344

10.  Mcl-1 Interacts with Akt to Promote Lung Cancer Progression.

Authors:  Guo Chen; Dongkyoo Park; Andrew T Magis; Madhusmita Behera; Suresh S Ramalingam; Taofeek K Owonikoko; Gabriel L Sica; Keqiang Ye; Chao Zhang; Zhengjia Chen; Walter J Curran; Xingming Deng
Journal:  Cancer Res       Date:  2019-10-29       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.